Recently, DNA oligonucleotide microarray gene expression analysis has been used to define molecular profiles of medulloblastomas, the most common malignant brain tumors of childhood (Pomeroy et al., 2002). Medulloblastomas were found to be molecularly distinct from other CNS embryonal tumors, and their histological subtypes had unique and functionally significant gene expression patterns. Gene expression profiles were highly predictive of response to therapy, predicting survival in a retrospective analysis with much greater accuracy than current clinical staging criteria or single marker gene outcome predictors. These results must now be prospectively validated before molecular markers can be used for risk stratification in future clinical trials. The experiments of this proposal are correlative biological studies of Phase III medulloblastoma therapy trials of the Children's Oncology Group (COG), designed to optimize and validate prognostic molecular markers.
In Specific Aim 1, a multi-molecular outcome predictor, based on gene expression profiles (Affymetrix Human Genome U133 arrays) of tumors from 500 children treated in COG medulloblastoma trials over the next 5 years, will be optimized, validated and developed for """"""""real time"""""""" analysis in the context of future clinical trials.
In Specific Aim 2, the gene expression database will be used to develop a molecular taxonomy, identifying subclasses of medulloblastomas defined by the expression profiles of molecular signaling pathways that promote tumorigenesis. Gene expression will be linked to oncogenic genomic mutations in Specific Aim 3, by combining expression profiling with genome-wide mutation analysis obtained from DNA BAC clone (Spectral Genomics) microarray-based comparative genomic hybridization. In achieving these Aims, we will create a comprehensive medulloblastoma gene expression and mutation database that is linked to clinical outcome of a large and well-characterized cohort of children. The data will hosted on the website of the NCI/NINDS Glioma Molecular Diagnostic Initiative that is being developed by Howard Fine of the NCI/NINDS Neuro-Oncology Branch and the NIH Bioinformatics group, so that investigators throughout the world can have free access to the molecular and clinical database generated by this project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA109467-05
Application #
7454434
Study Section
Special Emphasis Panel (ZRG1-CBSS (01))
Program Officer
Wu, Roy S
Project Start
2004-08-01
Project End
2011-05-31
Budget Start
2008-06-10
Budget End
2011-05-31
Support Year
5
Fiscal Year
2008
Total Cost
$744,419
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Waszak, Sebastian M; Northcott, Paul A; Buchhalter, Ivo et al. (2018) Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 19:785-798
Archer, Tenley C; Ehrenberger, Tobias; Mundt, Filip et al. (2018) Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 34:396-410.e8
Boulay, Gaylor; Awad, Mary E; Riggi, Nicolo et al. (2017) OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma. Cancer Discov 7:288-301
Kim, Jong Wook; Abudayyeh, Omar O; Yeerna, Huwate et al. (2017) Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst 5:105-118.e9
Northcott, Paul A; Buchhalter, Ivo; Morrissy, A Sorana et al. (2017) The whole-genome landscape of medulloblastoma subtypes. Nature 547:311-317
Archer, Tenley C; Mahoney, Elizabeth L; Pomeroy, Scott L (2017) Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics 14:265-273
Wang, Xiaofeng; Lee, Ryan S; Alver, Burak H et al. (2017) SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet 49:289-295
Huang, Franklin W; Mosquera, Juan Miguel; Garofalo, Andrea et al. (2017) Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discov 7:973-983
Hanaford, Allison R; Archer, Tenley C; Price, Antoinette et al. (2016) DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res 22:3903-14
Jonas, Oliver; Calligaris, David; Methuku, Kashi Reddy et al. (2016) First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol 12:1297-302

Showing the most recent 10 out of 64 publications